Global pharmaceutical leader Novo Nordisk has entered into a strategic partnership with Emcure Pharmaceuticals to introduce its revolutionary weight-loss and diabetes drug to the Indian market. This collaboration marks a pivotal moment in India’s healthcare landscape, as demand surges for advanced obesity and metabolic treatments. The alliance will combine Novo Nordisk’s innovation in metabolic therapies with Emcure’s strong domestic manufacturing and distribution capabilities.